John Henson, MD

Professor of Medicine, Neurology, Neurosurgery, Pediatrics Augusta University

  • Augusta GA

Dr. Henson practices neuro-oncology in the MCG Brain Tumor Program and manages patients with neurofibromatosis and related genetic disorders

Contact

Augusta University

View more experts managed by Augusta University

Multimedia

Biography

Dr. Henson practices neuro-oncology in the MCG Brain Tumor Program and manages patients with neurofibromatosis, tuberous sclerosis, von Hippel-Lindau and related genetic disorders in the MCG Neurofibromatosis Clinic. He has a broad clinical interest in hereditary cancer risk analysis and risk reduction and started the Hereditary Cancer Clinic at the Georgia Cancer Center. Dr. Henson trained in neurology at Vanderbilt University Medical Center and in neuro-oncology at Memorial Sloan-Kettering Cancer Center. He was director of the MGH Brain Tumor Center in Boston for many years, and also served as Chief of Oncology Services for Piedmont Healthcare, based in Atlanta. Dr. Henson studied genomic cancer risk assessment with Dr. Jeffrey Weitzel at City of Hope. Most recently he was medical director of the Ivy Center for Advanced Brain Tumor Treatment and Swedish Neurofibromatosis Center at Swedish Medical Center in Seattle. He is coauthor of the textbook Diagnosis and Management of Hereditary Cancer and has published over 150 papers, reviews, and books chapters.

Areas of Expertise

Hereditary Cancer
Neurofibromatosis
Genetics
Neuro-Oncology
Spine Tumors
Brain Tumors
Cancer

Accomplishments

Today’s Innovators Award, Georgia CORE (Center for Oncology Research and Education)

2023

Top Doc, Castle Connolly

2022 - 2023

Service Award, American College of Healthcare Executives

2018

Show All +

Education

University of Washington

MBA

Business Administrations, Management and Operatations

2013

Loma Linda University

M.D.

Medicine

1984

Southern Adventist University

B.A.

Biology/Biological Sciences, General

1980

Affiliations

  • American Academy of Neurology : Member
  • American College of Healthcare Executive : Member
  • American Neurological Association : Member
  • American Society of Clinical Oncology : Member
  • American Society of Human Genetics : Member
Show All +

Articles

Associations of practical, emotional, and physical problems with psychosocial distress among cancer patients

Journal of Psychosocial Oncology

2022

Objective: To better understand the relationship between cancer patient distress and psychosocial variables, including problem types, to improve ability to predict and address psychosocial need.

Methods: A variation of National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) was administered and collected at four sites from an Integrated Network Cancer Program (INCP). The presence of moderate/severe distress was examined relative to patient demographics, disease characteristics, and psychosocial problems.

[...]

View more

Impact of neurofibromatosis type 1 in an adult community population

Neuro-Oncology Practice

2022

Background: Neurofibromatosis type 1 (NF1) is a common tumor predisposition syndrome with varying manifestations and severity. Adult NF1 patients often experience fragmented care, so we sought to characterize the health and demographic features of a community-based population of adults with NF1 and hypothesized that lack of a specialty clinic for adult NF1 patients correlates with unmet needs.

[...]

View more

Paired Tumor-Germline Testing as a Driver in Better Cancer Care

JAMA Network Open

2022

Yap et al provide an analysis of paired tumor-germline next-generation sequencing (NGS) in a large population of patients with cancer. One implication of the data is that paired testing provides important information about a patient’s cancer and its treatment and can address hereditary issues of importance to the patient’s family. This commentary considers the advantages of paired tumor-germline testing in cancer care.

View more

Show All +